Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Total Liabilities
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has total liabilities worth €47.87 Billion EUR (≈ $55.96 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Guangzhou Baiyunshan Pharmaceutical Hold long-term investment allocation to see how much of total assets are deployed in long-term investments.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Guangzhou Baiyunshan Pharmaceutical Hold asset portfolio.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Total Liabilities
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lendingtree Inc
NASDAQ:TREE
|
USA | $590.86 Million |
|
CTOS Digital Bhd
KLSE:5301
|
Malaysia | RM211.19 Million |
|
Kona I Co.Ltd
KQ:052400
|
Korea | ₩270.50 Billion |
|
Kap Industrial Holdings Ltd
JSE:KAP
|
South Africa | ZAC17.00 Billion |
|
BNY Mellon Strategic Municipals Inc
NYSE:LEO
|
USA | $228.40 Million |
|
SSE PLC
LSE:SSE
|
UK | GBX21.94 Billion |
|
Xinxiang Tianli Energy Co. Ltd. A
SHE:301152
|
China | CN¥1.37 Billion |
|
Integrated Service Technology
TWO:3289
|
Taiwan | NT$3.89 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See GU5 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2025)
The table below shows the annual total liabilities of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €44.43 Billion ≈ $51.94 Billion |
+1.17% |
| 2024-12-31 | €43.91 Billion ≈ $51.34 Billion |
+4.78% |
| 2023-12-31 | €41.91 Billion ≈ $49.00 Billion |
+2.15% |
| 2022-12-31 | €41.03 Billion ≈ $47.97 Billion |
+17.93% |
| 2021-12-31 | €34.79 Billion ≈ $40.67 Billion |
+10.26% |
| 2020-12-31 | €31.55 Billion ≈ $36.89 Billion |
+2.11% |
| 2019-12-31 | €30.90 Billion ≈ $36.13 Billion |
+9.05% |
| 2018-12-31 | €28.34 Billion ≈ $33.13 Billion |
+213.08% |
| 2017-12-31 | €9.05 Billion ≈ $10.58 Billion |
+9.80% |
| 2016-12-31 | €8.24 Billion ≈ $9.64 Billion |
+14.70% |
| 2015-12-31 | €7.19 Billion ≈ $8.40 Billion |
+13.27% |
| 2014-12-31 | €6.34 Billion ≈ $7.42 Billion |
+21.39% |
| 2013-12-31 | €5.23 Billion ≈ $6.11 Billion |
-- |
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more